Literature DB >> 28630191

Ceftazidime-Avibactam and Aztreonam, an Interesting Strategy To Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae and Pseudomonas aeruginosa.

Benjamin Davido1, Lesly Fellous2, Christine Lawrence3,4, Virginie Maxime5, Martin Rottman4,6, Aurélien Dinh7.   

Abstract

Entities:  

Keywords:  avibactam; aztreonam; ceftazidime

Mesh：

Substances：

Year:  2017        PMID： 28630191      PMCID： PMC5571320          DOI： 10.1128/AAC.01008-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  3 in total

1.  Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae?

Authors:  Steven Marshall; Andrea M Hujer; Laura J Rojas; Krisztina M Papp-Wallace; Romney M Humphries; Brad Spellberg; Kristine M Hujer; Emma K Marshall; Susan D Rudin; Federico Perez; Brigid M Wilson; Ronald B Wasserman; Linda Chikowski; David L Paterson; Alejandro J Vila; David van Duin; Barry N Kreiswirth; Henry F Chambers; Vance G Fowler; Michael R Jacobs; Mark E Pulse; William J Weiss; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

2.  In Vitro Discordance with In Vivo Activity: Humanized Exposures of Ceftazidime-Avibactam, Aztreonam, and Tigecycline Alone and in Combination against New Delhi Metallo-β-Lactamase-Producing Klebsiella pneumoniae in a Murine Lung Infection Model.

Authors:  M L Monogue; L M Abbo; R Rosa; J F Camargo; O Martinez; R A Bonomo; D P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

3.  Susceptibility to cephalosporin combinations and aztreonam/avibactam among third-generation cephalosporin-resistant Enterobacteriaceae recovered on hospital admission.

Authors:  Alexander Mischnik; Philipp Baumert; Axel Hamprecht; Anna Rohde; Silke Peter; Susanne Feihl; Johannes Knobloch; Hanna Gölz; Axel Kola; Birgit Obermann; Christiane Querbach; Matthias Willmann; Friedemann Gebhardt; Evelina Tacconelli; Petra Gastmeier; Harald Seifert; Winfried V Kern
Journal:  Int J Antimicrob Agents       Date:  2016-11-28       Impact factor: 5.283
  3 in total
  36 in total

Review 1.  Therapies for multidrug resistant and extensively drug-resistant non-fermenting gram-negative bacteria causing nosocomial infections: a perilous journey toward 'molecularly targeted' therapy.

Authors:  Nadim G El Chakhtoura; Elie Saade; Alina Iovleva; Mohamad Yasmin; Brigid Wilson; Federico Perez; Robert A Bonomo
Journal:  Expert Rev Anti Infect Ther       Date:  2018-01-16       Impact factor: 5.091

Review 2.  Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in Children.

Authors:  Kathleen Chiotos; Molly Hayes; Jeffrey S Gerber; Pranita D Tamma
Journal:  J Pediatric Infect Dis Soc       Date:  2020-02-28       Impact factor: 3.164

3.  NG-Test Carba 5 for Rapid Detection of Carbapenemase-Producing Enterobacterales from Positive Blood Cultures.

Authors:  Julie Takissian; Rémy A Bonnin; Thierry Naas; Laurent Dortet
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

4.  Successful Treatment of Bacteremia Due to NDM-1-Producing Morganella morganii with Aztreonam and Ceftazidime-Avibactam Combination in a Pediatric Patient with Hematologic Malignancy.

Authors:  Claire Amaris Hobson; Stéphane Bonacorsi; Mony Fahd; André Baruchel; Aurélie Cointe; Nora Poey; Hervé Jacquier; Catherine Doit; Audrey Monjault; Olivier Tenaillon; André Birgy
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

Review 5.  Metallo-β-Lactamases: Structure, Function, Epidemiology, Treatment Options, and the Development Pipeline.

Authors:  Sara E Boyd; David M Livermore; David C Hooper; William W Hope
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

Review 6.  Resistance to Novel β-Lactam-β-Lactamase Inhibitor Combinations: The "Price of Progress".

Authors:  Krisztina M Papp-Wallace; Andrew R Mack; Magdalena A Taracila; Robert A Bonomo
Journal:  Infect Dis Clin North Am       Date:  2020-09-30       Impact factor: 5.982

7.  Aztreonam plus Clavulanate, Tazobactam, or Avibactam for Treatment of Infections Caused by Metallo-β-Lactamase-Producing Gram-Negative Bacteria.

Authors:  Cécile Emeraud; Lelia Escaut; Athénaïs Boucly; Nicolas Fortineau; Rémy A Bonnin; Thierry Naas; Laurent Dortet
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

Review 8.  NDM Metallo-β-Lactamases and Their Bacterial Producers in Health Care Settings.

Authors:  Wenjing Wu; Yu Feng; Guangmin Tang; Fu Qiao; Alan McNally; Zhiyong Zong
Journal:  Clin Microbiol Rev       Date:  2019-01-30       Impact factor: 26.132

9.  Transplant tourism complicated by life-threatening New Delhi metallo-β-lactamase-1 infection.

Authors:  Jenell Stewart; Gretchen Snoeyenbos Newman; Rupali Jain; Andrew Bryan; Heather Berger; Martin Montenovo; Ramasamy Bakthavatsalam; Catherine E Kling; Lena Sibulesky; Sherene Shalhub; Ajit P Limaye; Cynthia E Fisher; Robert M Rakita
Journal:  Am J Transplant       Date:  2018-10-29       Impact factor: 8.086

Review 10.  Pharmacological aspects and spectrum of action of ceftazidime-avibactam: a systematic review.

Authors:  Felipe Francisco Tuon; Jaime L Rocha; Marcelo R Formigoni-Pinto
Journal:  Infection       Date:  2017-11-07       Impact factor: 3.553
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.